Cancer types
  • Lymphomas
Title of study
BETER-REFLECTIE STUDY: Role of genomic factors on late adverse events after lymphoma
Version Number
Approval Date 
4, 23 March 2021
Short Title
BETER-REFLECTIE
Study site
Principle Investigator
Prof. dr. ir. F.E. van Leeuwen
Investigator Maastro
Drs. B.D.P. Ta
Sponsor
Nederlands Kanker Instituut/ Antoni van Leeuwenhoek (NKI-AVL)
Trial registry
Objectives 

The primary objectives are to identify genomic determinants of late adverse events in 5-year lymphoma survivors and to assess the role of patient-and treatment-related factors herein.
Secondary objectives:
• Unravel the underlying molecular mechanisms that lead to adverse events observed in lymphoma survivors, including evaluation of the functional impact of identified genomic risk factors.
• Assess the association of genomic markers with other late adverse events and (intermediate) parameters of treatment-associated toxicity, such as the metabolic syndrome.
• Assess the molecular profile of treatment-induced SMNs.

Primary Endpoint 

The main study endpoints are the occurrence of clinically diagnosed SMNs and CVD at least 5 years after treatment for lymphoma.

Secondary Endpoints 

• The occurrence of other late adverse events and (intermediate) parameters of treatment-associated toxicity.
• The functional impact of identified genomic markers on relevant gene and protein expressionlevels. – The molecular profile of treatment-induced SMNs.

X